Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00417716
Status:
WITHDRAWN
Last Update Posted:
2024-06-03
First Post:
2006-06-30
Brief Title:
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
Sponsor:
Asociación para Evitar la Ceguera en México
Organization:
Asociación para Evitar la Ceguera en México
Study Overview
Official Title:
The Efficacy of a Single Intravitreal Injection of Bevacizumab in Patients With Diffuse Diabetic Macular Edema
Status:
WITHDRAWN
Status Verified Date:
2024-05
Last Known Status:
Active not recruiting
Delayed Posting:
No
If Stopped, Why?:
Poor accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema
Detailed Description:
A non-randomized prospective clinical interventional study which includes 45 non previously treated patients with DME The patients received a single intravitreal injection of 25 mg bevacizumab Follow-up included clinical examination best corrected visual acuity BCVA intraocular pressure IOP cataract grading DME characteristics and systemic check-up pre-injection at first visit at weeks 1 and 2 and months 1 and 3 OCT and fluorescein angiography was evaluated at months 1 and 3
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None